Progressive supranuclear palsy is a rare, degenerative brain disease caused by the abnormal buildup of a protein called tau in neurons and surrounding cells, leading to difficulties with balance, eye movement, swallowing, and thinking. It belongs to a family of conditions known as tauopathies and is the most common form of atypical parkinsonism, meaning it shares some features with Parkinson’s disease but follows a different and generally faster course. Despite being identified more than half a century ago, PSP remains frequently misdiagnosed, undertreated, and poorly understood by the general public.
How PSP Was Discovered and Why It Took So Long to Recognize
In the late 1950s and early 1960s, Canadian neurologist J. Clifford Richardson noticed a cluster of patients in Toronto who shared a puzzling set of symptoms: they couldn’t look up or down voluntarily, they fell frequently, their necks were stiff and extended rather than stooped, and their thinking slowed down. Richardson predicted that the clinical picture would eventually turn out to be broader than what he first saw, and that the disease was not unique to Toronto.1PubMed. J. Clifford Richardson and 50 years of progressive supranuclear palsy That prediction proved correct: what Richardson described turned out to be only the most recognizable face of a disease with many possible presentations.
The Classic Presentation and Its Hallmark Symptoms
The form Richardson originally described is now called PSP-Richardson syndrome (PSP-RS), and it remains the most common variant, accounting for roughly half of all confirmed cases.2Brain. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism Its defining features are vertical gaze palsy, especially difficulty looking downward; early and repeated falls, often backward; stiffness of the trunk and neck; and a pattern of cognitive decline that primarily affects planning, decision-making, and behavioral control.3PubMed Central. Richardson Syndrome Variant of Progressive Supranuclear Palsy: A Case Report
The eye movement problem is one of the most distinctive clues. In PSP, the brain’s ability to command voluntary vertical eye movements breaks down, while reflexive eye movements (like those triggered when a doctor tips your head forward) are preserved early on. This mismatch is what “supranuclear” refers to: the problem sits above the nerve nuclei that physically control the eye muscles. The gaze palsy tends to start subtly, with slowed downward saccades, before evolving into a near-complete inability to look down. That impairment makes everyday activities like reading, eating, and navigating stairs surprisingly dangerous.
Falls are often the very first symptom, sometimes appearing a year or more before a diagnosis is made. They differ from falls in Parkinson’s disease in a telling way: people with PSP tend to fall backward and without attempting to catch themselves, as though they have lost the instinctive sense that they are tipping. A brainstem region called the pedunculopontine nucleus, which helps coordinate posture and gait, loses a striking proportion of its neurons in PSP, with reductions measured between roughly 50 and 70 percent in autopsy studies.4PubMed. Loss of pedunculopontine neurons in progressive supranuclear palsy That same region also shows reduced levels of an enzyme needed to produce the neurotransmitter acetylcholine, compounding the problem.5PubMed Central. Falls in Progressive Supranuclear Palsy
Not Everyone Gets the Classic Version
One of the most important things to know about PSP is that about a third of people confirmed to have it at autopsy never fit the classic Richardson picture during their lifetime.6Brain. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson’s syndrome and PSP-parkinsonism The disease has at least a dozen recognized clinical variants, and the Movement Disorder Society’s updated diagnostic criteria reflect this reality by allowing diagnoses of possible PSP even when the classic gaze palsy is absent.
A study of 112 patients classified them into ten distinct phenotypes. Beyond PSP-RS, the most common were PSP-parkinsonism (PSP-P), which looks more like Parkinson’s disease with some tremor and asymmetric symptoms, and several cortical variants that primarily affect language, behavior, or limb coordination.7Journal of Movement Disorders. Phenotypic Spectrum of Progressive Supranuclear Palsy: Clinical Study and Apolipoprotein E Effect Rarer forms include PSP with progressive gait freezing, where patients’ feet seem glued to the floor when they try to walk, and PSP with predominant cerebellar features. Brain imaging confirms that these variants are not just clinical quirks: PSP-P and PSP with gait freezing show more restricted patterns of brain shrinkage and tau accumulation, concentrated in deep brain structures like the putamen and globus pallidus, compared to the broader damage seen in Richardson syndrome.8NeuroImage: Clinical. Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants
Presentations other than PSP-RS accounted for a large majority of autopsy-confirmed cases in one recent series, and those patients met older diagnostic criteria at lower rates and much later in the disease. The updated Movement Disorder Society criteria try to address this by stratifying diagnoses into probable, possible, and suggestive categories, each allowing different symptom combinations.
What Tau Does to the Brain in PSP
PSP is fundamentally a disease of tau protein gone wrong. Tau normally stabilizes tiny internal scaffolding structures inside neurons, but in PSP a particular form of tau with four binding repeats (called 4-repeat tau) becomes abnormally modified, clumps together, and builds up inside cells. What sets PSP apart from other tauopathies like Alzheimer’s disease is where and in what cells these clumps appear. Neurons develop tangles with a distinctive rounded “globose” shape, support cells called oligodendrocytes develop structures known as coiled bodies, and star-shaped brain cells called astrocytes accumulate tau in a pattern unique to PSP: spiky, radiating formations called tufted astrocytes.9PubMed. Tau accumulation in astrocytes in progressive supranuclear palsy is a degenerative rather than a reactive process These tufted astrocytes are so characteristic that finding them at autopsy is essentially diagnostic.10PubMed Central. Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration
Research increasingly points to tau spreading through connected brain circuits in a prion-like fashion, hopping from one neuron to the next at the points where they communicate. A study using high-resolution imaging of synapses in frontal cortex tissue from PSP patients found that a postsynaptic terminal was 86 times more likely to contain tau if the presynaptic terminal it was paired with also contained tau, far exceeding what chance alone would predict.11PubMed Central. Trans-synaptic tau propagation in progressive supranuclear palsy In a primate study, tau extracted from the brains of PSP patients and injected into macaques produced the full range of PSP-like pathology (globose tangles, tufted astrocytes, coiled bodies) not only near the injection site but in connected brain regions, along with motor and behavioral impairments resembling the disease.12Brain. Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates This evidence bolsters the idea that once tau pathology begins in one brain region, it can seed itself outward along neural highways.
Genetics and Environmental Risk
PSP is not typically inherited in a simple way, but genetics clearly influence who gets it. The strongest genetic risk factor is a common variant of the MAPT gene, which encodes tau itself. A particular version of this gene region, called the H1 haplotype (and a sub-variant called H1c), is significantly overrepresented in people with PSP.13Journal of Movement Disorders. Genetics of Progressive Supranuclear Palsy Genome-wide studies have identified additional risk sites on other chromosomes, including genes involved in protein trafficking and cellular stress responses.14PubMed Central. Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases
In rare families, specific mutations in MAPT cause PSP directly, with 15 different mutations identified so far. Mutations in the LRRK2 gene (better known for its role in Parkinson’s disease) and in the DCTN1 gene can also produce a PSP-like picture, though both are uncommon causes.15PubMed Central. Genetics of Progressive Supranuclear Palsy: A Review For the vast majority of patients, however, PSP appears to arise from some interplay of genetic susceptibility and environmental exposures accumulated over a lifetime.
On the environmental side, the evidence is thinner but suggestive. A review of available studies found that exposures to dietary toxins, certain metals, well water, and a history of hypertension were all associated with increased PSP risk.16PubMed Central. Environmental Risk Factors for Progressive Supranuclear Palsy A case-control study that started with a broad list of occupational and lifestyle factors found that, after adjusting for other variables, only prolonged drinking of well water remained a significant risk factor, alongside an inverse association with having a college degree.17PubMed Central. Environmental and Occupational Risk Factors for Progressive Supranuclear Palsy: Case-Control Study These findings are intriguing but hard to act on, and they have not been replicated as consistently as the genetic associations.
How PSP Is Diagnosed
Diagnosis in life remains a clinical exercise, meaning it depends on a neurologist recognizing the pattern of symptoms and ruling out other conditions. There is no blood test or genetic screen that can confirm PSP. Brain MRI helps: atrophy of the midbrain, particularly the upper portion, produces a distinctive silhouette on sagittal images known as the hummingbird sign (because the shrunken midbrain looks like a hummingbird’s head and beak relative to the pons below).18PubMed Central. Hummingbird sign in progressive supranuclear palsy disease When present, this sign is extremely specific for PSP, with a positive predictive value over 96 percent, but it misses roughly half of all cases because midbrain atrophy may not be obvious early in the disease.19PubMed. The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism The midbrain shrinkage reflects damage to a nucleus involved in controlling vertical eye movements, which explains why gaze palsy and midbrain atrophy track together.20PubMed. Study of the rostral midbrain atrophy in progressive supranuclear palsy
Newer imaging tools are being developed to detect tau deposits directly in living brains. PET scans using tau-binding tracers have shown promise in distinguishing PSP from healthy controls and from other parkinsonian conditions like Parkinson’s disease and dementia with Lewy bodies.21PubMed Central. Feasibility of short imaging protocols for [(18)F]PI-2620 tau-PET in progressive supranuclear palsy One tracer, florzolotau, produced distribution patterns in living PSP brains that closely matched what autopsy studies have found, with binding intensity that tracked clinical severity.22PubMed Central. (18)F-Florzolotau PET imaging captures the distribution patterns and regional vulnerability of tau pathology in progressive supranuclear palsy Combining tau PET with MRI measurements and cerebrospinal fluid markers like neurofilament light chain (a marker of nerve cell damage) can further sharpen diagnostic accuracy.23PubMed. Performance of [(18)F]RO948 PET, MRI and CSF neurofilament light in the differential diagnosis of progressive supranuclear palsy These tools are still largely confined to research settings, but they represent a genuine step toward earlier and more confident diagnosis.
Cognitive and Behavioral Changes
People often think of PSP as a movement disorder, and the falls and gaze problems do tend to dominate the clinical picture. But cognitive and behavioral changes are woven into the disease from the start. The cognitive profile differs from Alzheimer’s disease: memory is often relatively preserved early on, while the ability to plan, shift attention, organize tasks, and control impulses deteriorates. Apathy is common and can be profoundly disabling, sometimes mistaken for depression. Impulsivity is another frequent feature, leading to risky decisions or inappropriate social behavior.24PubMed Central. Managing cognition in progressive supranuclear palsy
These behavioral changes are among the hardest aspects for families to navigate. A person with PSP who becomes apathetic may stop initiating conversations, neglect hygiene, or sit passively for hours, not because they are depressed but because the frontal circuits that drive motivation have been damaged. Conversely, someone with the impulsive subtype may attempt risky actions like standing up quickly without support despite repeated falls. Neither pattern responds well to standard psychiatric medications, and some of those drugs can make balance problems worse.
Treatment Options and Their Limits
No medication slows or stops PSP. Treatment is symptomatic and often disappointing compared to what is available for Parkinson’s disease. Levodopa, the cornerstone drug for Parkinson’s, produces at most a mild benefit in roughly 30 percent of PSP patients, and even that tends to be vague improvements in mobility or energy rather than the dramatic response seen in Parkinson’s. A dose of 750 to 1,000 milligrams daily should be tried before concluding that levodopa is unhelpful.25Practical Neurology. Progressive supranuclear palsy: diagnosis and management Any benefit, where present, is often short-lived.26PubMed Central. Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options
Dystonia, particularly painful neck spasms that can interfere with swallowing and social interaction, is one of the more treatable individual symptoms. Botulinum toxin injections, especially when combined with physical therapy, are the most effective approach. Topical anti-inflammatory drugs can help with shoulder dystonia as a first step. Amantadine is sometimes tried but rarely sufficient on its own. Drugs that boost acetylcholine are generally avoided because they tend to worsen cognition, balance, and fall risk.27Practical Neurology. Progressive supranuclear palsy: diagnosis and management Excessive drooling, caused by impaired swallowing rather than overproduction of saliva, can be managed with botulinum toxin injected into the salivary glands.28PubMed Central. Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options
Physical therapy and occupational therapy are arguably more valuable than any pill. Strategies to reduce fall risk, weighted walkers, gait training, and home modifications can preserve independence longer. Speech and language therapy helps with both communication and swallowing safety, since aspiration pneumonia (caused by food or liquid entering the lungs) is one of the leading causes of death in PSP.
Why Anti-Tau Drugs Have Not Worked Yet
Because tau pathology is central to PSP, there has been significant investment in therapies designed to neutralize or clear abnormal tau from the brain.29PubMed Central. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches The results so far have been humbling. Gosuranemab, an antibody targeting the free-floating N-terminal fragment of tau, was tested in a large, well-powered trial of 486 participants. It successfully reduced its target in cerebrospinal fluid by 98 percent, proving it reached the brain and did what it was designed to do biochemically. Yet there was no meaningful clinical benefit: patients on the drug declined at virtually the same rate as those on placebo.30PubMed Central. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
This disconnect between hitting the biological target and helping the patient has forced researchers to rethink what form of tau actually drives the disease. If the N-terminal fragments floating in spinal fluid are not the toxic species, then mopping them up will not help even if you do it very efficiently. Attention has shifted toward targeting aggregated tau within cells, tau seeds that spread between neurons, and the cellular machinery that allows tau to propagate. The primate research showing that PSP-derived tau seeds can reproduce the disease in connected brain regions gives this approach biological plausibility, but translating it into a workable drug remains a major challenge.
The Weight on Caregivers
PSP places an unusually heavy burden on the people providing daily care. Compared to many neurological conditions, PSP combines physical dependency with behavioral changes in a way that escalates quickly. One longitudinal study found that caregiver strain increased by 25 to 30 percent over just two years and was significantly greater in PSP than in the related condition corticobasal syndrome. The patient factors most strongly linked to caregiver distress were apathy, depression, irritability, poor judgment, and impaired ability to perform daily activities.31PubMed Central. Caregiver strain in progressive supranuclear palsy and corticobasal syndromes Female caregivers were at particular risk for developing depression themselves.
An earlier study found that burden increased steeply during the first 18 months after diagnosis and then plateaued, not because things got easier but because caregivers had adjusted to a demanding baseline. Women reported more burden than men even after controlling for disease severity.32PubMed. Caregiving in progressive supranuclear palsy These findings underscore the importance of early and repeated assessment of caregiver wellbeing, ideally starting at the time of diagnosis rather than waiting for a crisis.
Palliative care referral is worth considering earlier than families might expect. A study of advanced PSP patients admitted to a palliative care unit found that the most common triggers for admission were swallowing difficulties, falls, pain, communication impairment, and respiratory symptoms. In about two-thirds of admission episodes, patients stabilized or improved enough to go home, with an average stay of about 12 days.33PubMed. Managing Advanced Progressive Supranuclear Palsy and Corticobasal Degeneration in a Palliative Care Unit: Admission Triggers and Outcomes Palliative care in this context is not about end-of-life measures; it is about managing pain, optimizing swallowing safety, and giving caregivers a necessary break.
Animal Models and the Search for Better Treatments
Developing treatments for PSP has been hampered by the difficulty of replicating the disease in laboratory animals. Standard mice engineered to express abnormal human tau develop some neurodegenerative features, but early models failed to produce the glial tau pathology that defines PSP in humans. A transgenic mouse line engineered to overexpress human tau in both neurons and glial cells was a step forward: these mice developed age-dependent accumulations of insoluble tau in glial cells, along with structures resembling the astrocytic plaques of corticobasal degeneration and the coiled bodies seen in both PSP and CBD.34Neuron. Transgenic Mouse Model of Progressive Supranuclear Palsy and Corticobasal Degeneration
The primate seeding model represents a newer and arguably more faithful approach. When tau extracted from PSP patients was injected into macaque brains, it reproduced not just the molecular pathology but also motor and behavioral symptoms, and it spread through connected brain regions in a pattern consistent with the human disease.35Brain. Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates This model could serve as a testing ground for therapies aimed at blocking tau propagation, though primate studies are slow, expensive, and ethically complex. The gap between a promising animal model and an effective human therapy remains wide, but these tools at least give researchers a more realistic picture of how PSP-type tau behaves in a living brain.